Michael Recht - Concepedia

Author

Michael Recht

Oregon Health & Science University ORCID

Also Known As

Hooper, W. Craig, Kevin McRedmond, Kristina M Haley, M Recht, M. RECHT, M. Recht, Michael Recht, Recht M, Recht, M, Recht, Michael

255

Publications

7.7K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University American Thrombosis and Hemostasis Network Novo Nordisk (United States)Emory University Indiana Hemophilia and Thrombosis Center

About

Michael Recht is an author at Oregon Health & Science University specializing in medicine, hematology, and thrombosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	20	973
2	Health Sciences	8	8	539
3	Public Health	3	3	93
4	Education	1	1	26
5	Social Sciences	1	1	13

Michael Recht

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia Marilyn J. Manco‐Johnson, Thomas C. Abshire, Amy D. Shapiro, New England Journal of Medicine	2007	1.9K
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B Amit Nathwani, Ulreke M. Reiss, Edward G. D. Tuddenham, New England Journal of Medicine	2014	1.2K
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B Steven W. Pipe, Frank W.G. Leebeek, Michael Recht, New England Journal of Medicine	2023	307
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A Lindsey A. George, Paul E. Monahan, M. Elaine Eyster, New England Journal of Medicine	2021	234
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma Michael Recht, Ernest C. Borden, E. Knight The Journal of Immunology	1991	178
Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia Gregory J. Gerstner, Mary Lou Damiano, Abdel Rahman El Tom, Haemophilia Bone DiseaseBone HealthVitamin D InsufficiencyOrthopaedic SurgeryHealth Sciences	2009	144
Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach–Merritt phenomenon Yvonne E. Chiu, Beth A. Drolet, Francine Blei, Pediatric Blood & Cancer	2012	126
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B Annette von Drygalski, Adam Giermasz, Giancarlo Castaman, Blood Advances	2019	124
Self‐reported prevalence, description and management of pain in adults with haemophilia: methods, demographics and results from the Pain, Functional Impairment, and Quality of life (P‐FiQ) study Michelle Witkop, Anne T. Neff, Tyler W. Buckner, Haemophilia	2017	118
Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study Beth Boulden Warren, Dianne Thornhill, Jill Stein, Blood Advances	2020	116

Page 1